A Urine Test That Could Change the Course of Bladder Cancer Care - Stanford Medicine
A Urine Test That Could Change the Course of Bladder Cancer Care Stanford Medicine
Bladder Cancer News
BRAVO Study Examines Cost and Recurrence Outcomes of Blue Light Cystoscopy in NMIBC - Stephen Williams - UroToday
BRAVO Study Examines Cost and Recurrence Outcomes of Blue Light Cystoscopy in NMIBC - Stephen Williams UroToday
FDA grants Breakthrough Device Designation to urine-based multi-cancer early detection test - Urology Times
FDA grants Breakthrough Device Designation to urine-based multi-cancer early detection test Urology Times
Neoadjuvant Disitamab Vedotin With Tislelizumab Shows Efficacy for HER2-Expressing MIBC - Renal and Urology News
Neoadjuvant Disitamab Vedotin With Tislelizumab Shows Efficacy for HER2-Expressing MIBC Renal and Urology News
First-Line Treatment for Advanced Bladder Cancer - Everyday Health
First-Line Treatment for Advanced Bladder Cancer Everyday Health
Doctors Say This Is the Number-1 Sign of Bladder Cancer - Prevention
Doctors Say This Is the Number-1 Sign of Bladder Cancer Prevention
ctDNA Testing Is Poised to Reshape Risk Assessment and Treatment Decision-Making in Bladder Cancer - OncLive
ctDNA Testing Is Poised to Reshape Risk Assessment and Treatment Decision-Making in Bladder Cancer OncLive
Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms - ASCO Publications
Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms ASCO Publications
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study - TMX Newsfile
Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study TMX Newsfile
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer - NEJM
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer NEJM
All treated animals stayed cancer-free in Theralase bladder study - Stock Titan
All treated animals stayed cancer-free in Theralase bladder study Stock Titan
Yale Launches Innovative Clinical Trial for Metastatic Bladder Cancer - Yale School of Medicine
Yale Launches Innovative Clinical Trial for Metastatic Bladder Cancer Yale School of Medicine
Can ctDNA Predict Metastatic Risk in Bladder Cancer? - Oncology News Central
Can ctDNA Predict Metastatic Risk in Bladder Cancer? Oncology News Central
Bladder Cancer Therapy Enfortumab Vedotin (Padcev) Approved by FDA for More Patients - Memorial Sloan Kettering Cancer Center
Bladder Cancer Therapy Enfortumab Vedotin (Padcev) Approved by FDA for More Patients Memorial Sloan Kettering Cancer Center
Mount Sinai Study Identifies Inflammatory Immune Pathway Driving Immunotherapy Resistance in Bladder Cancer - Mount Sinai
Mount Sinai Study Identifies Inflammatory Immune Pathway Driving Immunotherapy Resistance in Bladder Cancer Mount Sinai
New drug developed at UC Davis offers hope to bladder cancer patients - University of California - Davis Health
New drug developed at UC Davis offers hope to bladder cancer patients University of California - Davis Health
Hypoxia-inducible factor 1α exerts dual roles in bladder cancer progression through TIMP3-mediated regulation of angiogenesis and invasion | Scientific Reports - Nature
Hypoxia-inducible factor 1α exerts dual roles in bladder cancer progression through TIMP3-mediated regulation of angiogenesis and invasion | Scientific Reports Nature
Study finds link between colorblindness and death from bladder cancer - Stanford Medicine
Study finds link between colorblindness and death from bladder cancer Stanford Medicine
Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer - ASCO Publications
Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer ASCO Publications
A multi-modal approach for decision making in bladder cancer - Nature
A multi-modal approach for decision making in bladder cancer Nature
TOBY Receives FDA Breakthrough Device Designation for Its Urine-Based Multi-Cancer Early Detection (MCED) Test - PR Newswire
TOBY Receives FDA Breakthrough Device Designation for Its Urine-Based Multi-Cancer Early Detection (MCED) Test PR Newswire
CystoDS: a multiclass endoscopy image dataset for artificial intelligence-assisted bladder cancer detection - Nature
CystoDS: a multiclass endoscopy image dataset for artificial intelligence-assisted bladder cancer detection Nature
IU researchers play role in development of new bladder cancer treatment - Indianapolis Business Journal
IU researchers play role in development of new bladder cancer treatment Indianapolis Business Journal
Mayo Clinic expert highlights improved survival in muscle-invasive bladder cancer and kidney cancer - Mayo Clinic News Network
Mayo Clinic expert highlights improved survival in muscle-invasive bladder cancer and kidney cancer Mayo Clinic News Network
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer? - The ASCO Post
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer? The ASCO Post
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies - Nature
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies Nature
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations - ImmunityBio
New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations ImmunityBio
USC study suggests type 1 diabetes may significantly raise bladder cancer risk - Keck School of Medicine of USC
USC study suggests type 1 diabetes may significantly raise bladder cancer risk Keck School of Medicine of USC
Bladder Cancer Remission Rate: What Patients Need to Know in 2025 - Oncodaily
Bladder Cancer Remission Rate: What Patients Need to Know in 2025 Oncodaily
Top 10 Urology Times bladder cancer articles of 2025 - Urology Times
Top 10 Urology Times bladder cancer articles of 2025 Urology Times
Bladder Cancer: What You Need to Know - CU Anschutz newsroom
Bladder Cancer: What You Need to Know CU Anschutz newsroom
Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer - Nature
Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer Nature
Non-Chemo, Biomarker-Driven Perioperative Strategies Highlight Bladder Cancer Presentations to Watch at ASCO GU 2026 - OncLive
Non-Chemo, Biomarker-Driven Perioperative Strategies Highlight Bladder Cancer Presentations to Watch at ASCO GU 2026 OncLive
HER2 in Bladder Cancer: A Frequent but Complex and Dynamic Biomarker - Daniele Raggi - UroToday
HER2 in Bladder Cancer: A Frequent but Complex and Dynamic Biomarker - Daniele Raggi UroToday
Urine DNA test predicts bladder cancer recurrence and guides BCG therapy - Labmate Online
Urine DNA test predicts bladder cancer recurrence and guides BCG therapy Labmate Online
New Gene Therapy Nears EU Nod for Bladder Cancer - Medscape
New Gene Therapy Nears EU Nod for Bladder Cancer Medscape
Groundbreaking Advances for Patients with Muscle-Invasive Bladder Cancer and More to Come - Memorial Sloan Kettering Cancer Center
Groundbreaking Advances for Patients with Muscle-Invasive Bladder Cancer and More to Come Memorial Sloan Kettering Cancer Center
Advances in the management of localized bladder cancers - Nature
Advances in the management of localized bladder cancers Nature
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial - The Lancet
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial The Lancet
Developing Clinical Complete Response Definitions for Muscle-Invasive Bladder Cancer - ASCO Daily News
Developing Clinical Complete Response Definitions for Muscle-Invasive Bladder Cancer ASCO Daily News